Trial Profile
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- Sponsors Calliditas Therapeutics; Pharmalink AB
- 19 Nov 2014 New trial record